Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.15 is 74% above its 5-year average of -0.57, near the high end of its 5-year range (-0.80–-0.14).
61.04% above its 12-month average of -0.39.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.07.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T17:22:33.958Z. Historical observations retain their original dates. Historical series through 2021-11-09.
EARNINGS PER SHARE (EPS)
-0.15
EARNINGS PER SHARE (EPS) AVG TTM
-0.39
EARNINGS PER SHARE (EPS) AVG 3Y
-0.55
EARNINGS PER SHARE (EPS) AVG 5Y
-0.57
EARNINGS PER SHARE (EPS) AVG 10Y
-0.54
EARNINGS PER SHARE (EPS) AVG 15Y
-1.08
EARNINGS PER SHARE (EPS) AVG 20Y
-1.55
CURRENT VS TTM AVG
+61.04%
CURRENT VS 3Y AVG
+72.60%
CURRENT VS 5Y AVG
+73.76%
CURRENT VS 10Y AVG
+72.39%
CURRENT VS 15Y AVG
+86.16%
CURRENT VS 20Y AVG
+90.33%
Lexicon Pharmaceuticals, Inc.
Market Cap
$770.68M
Earnings Per Share (EPS)
-0.15
TTM Avg
-0.39
3Y Avg
-0.55
5Y Avg
-0.57
Market Cap
$772.26M
Earnings Per Share (EPS)
-0.75
TTM Avg
-1.06
3Y Avg
-1.25
5Y Avg
-1.46
Market Cap
$764.15M
Earnings Per Share (EPS)
0.84
TTM Avg
0.43
3Y Avg
-11.54
5Y Avg
-7.53
Market Cap
$759.48M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.23
3Y Avg
-1.23
5Y Avg
-1.23
Market Cap
$785.86M
Earnings Per Share (EPS)
-0.10
TTM Avg
-0.20
3Y Avg
-0.27
5Y Avg
-0.29
Market Cap
$789.31M
Earnings Per Share (EPS)
-0.20
TTM Avg
0.10
3Y Avg
-0.30
5Y Avg
-1.16
Market Cap
$792.51M
Earnings Per Share (EPS)
-1.68
TTM Avg
0.05
3Y Avg
-1.18
5Y Avg
-0.72
Market Cap
$746.50M
Earnings Per Share (EPS)
-1.18
TTM Avg
-1.05
3Y Avg
-1.11
5Y Avg
-0.92
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexicon Pharmaceuticals, Inc. (LXRX) | $770.68M | -0.15 | -0.39 | -0.55 | -0.57 |
| Sana Biotechnology, Inc. (SANA)vs › | $772.26M | -0.75 | -1.06 | -1.25 | -1.46 |
| Apnimed, Inc. (APMD)vs › | $766.30M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $764.15M | 0.84 | 0.43 | -11.54 | -7.53 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $759.48M | N/A | -1.23 | -1.23 | -1.23 |
| Geron Corporation (GERN)vs › | $785.86M | -0.10 | -0.20 | -0.27 | -0.29 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $789.31M | -0.20 | 0.10 | -0.30 | -1.16 |
| AdaptHealth Corp. (AHCO)vs › | $792.51M | -1.68 | 0.05 | -1.18 | -0.72 |
| Design Therapeutics, Inc. (DSGN)vs › | $746.50M | -1.18 | -1.05 | -1.11 | -0.92 |
| Ardelyx, Inc. (ARDX)vs › | $802.13M | -0.23 | -0.22 | -0.29 | -0.62 |
Trailing EPS (TTM)
$-0.15
Forward EPS (Est.)
$-0.17
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.14 |
| 2024-12-31 | -0.63 |
| 2023-12-31 | -0.80 |
| 2022-12-31 | -0.62 |
| 2021-12-31 | -0.61 |
| 2020-12-31 | -0.63 |
| 2019-12-31 | 1.23 |
| 2018-12-31 | -1.14 |
| 2017-12-31 | -1.23 |
| 2016-12-31 | -1.36 |
| 2015-12-31 | -0.05 |
| 2014-12-31 | -1.31 |
| 2013-12-31 | -1.42 |
| 2012-12-31 | -1.58 |
| 2011-12-31 | -2.39 |
| 2010-12-31 | -2.35 |
| 2009-12-31 | -3.98 |
| 2008-12-31 | -3.93 |
| 2007-12-31 | -4.12 |
| 2006-12-31 | -5.68 |
| 2005-12-31 | -3.97 |
| 2004-12-31 | -5.21 |
| 2003-12-31 | -7.91 |
| 2002-12-31 | -7.99 |
| 2001-12-31 | -4.90 |
| 2000-12-31 | -4.37 |
| 1999-12-31 | -3.57 |
